Powder composition

Abstract

A solid powder composition comprising one or more particles comprising nitrite and a proton source. Also disclosed are pharmaceutical compositions comprising the solid powder composition, methods of making the solid powder composition, materials and devices comprising the solid powder composition, methods of making same and methods of implanting same in the human or animal body.

Description

[Technical field]

[0001] The present invention relates to a powder composition comprising a nitrite salt and a proton source. The present invention also relates to a method for producing such a powder composition, an article comprising the powder composition, the use of the powder composition in an article, and a method of treatment involving the powder composition. [Background technology]

[0002] Nitric oxide (NO) and nitric oxide precursors have been extensively tested as potential pharmaceutical agents. Considerable challenges remain associated with the efficient production and delivery of nitric oxide, other nitrogen oxides and their precursors to organisms and cells for treatment. A widely adopted system for the production of nitric oxide relies on the acidification of nitrite with a proton source, such as an acid, to first produce nitrous acid (HNO2), which then readily decomposes to hydrogen ions and water in addition to nitric oxide and nitrate. This decomposition can be represented by the following equilibrium equation (1): 3HNO2→2NO+NO3 - +H + +H2O (1)

[0003] The acid and nitrite are typically provided as separate aqueous solutions of predetermined concentrations. These two solutions are thus provided as a two-component system, allowing the two separate solutions to be combined at the time of need to prevent the release of nitric oxide before it is needed.

[0004] Combining a two-component system at the time of need can result in, for example, inaccuracies in dosing when combining the two components. It is desirable to provide the nitrite and acidification source as a single component. Furthermore, providing a single-component product can reduce packaging. However, the classical two-component solution approach to acidifying nitrite cannot be provided as a single component system because the system may lose a significant amount of its nitric oxide during the manufacturing stage and not provide enough nitric oxide at the time of need. Summary of the Invention

[0005] Summary of the Invention The inventors have not only sought to provide a single component system for the delivery of nitric oxide by acidification of nitrite, but also to provide a solid form for this system which delivers significant amounts of nitric oxide when the solid form is in contact with an aqueous environment.

[0006] Most generally, the invention provides a solid powder composition comprising nitrite and a proton source in solid form, where at least a portion of the nitrite and at least a portion of the proton source are inseparable when dispersed in a medium or on a surface. In this manner, at least a portion of the nitrite and at least a portion of the proton source remain in close proximity (or intimately associated) and provide acidification of the nitrite when contacted with an aqueous environment.

[0007] The powder composition is acidified by mixing a solution of a proton source with a solution of a nitrite source and removing the solvent before significant acidification of the nitrite occurs. In this manner, the composition may comprise one or more particles that contain effective amounts of both the nitrite and the proton source in the same particle.

[0008] In a first aspect, the present invention provides a solid powder composition comprising one or more particles comprising a nitrite salt and a proton source.

[0009] In a second aspect, the present invention provides a solid powder composition comprising one or more particles formed by removal of solvent from a mixture comprising a nitrite salt solution and a proton source solution in less than one second (e.g., by spray drying) and / or under reaction-delaying conditions (e.g., freeze-drying).

[0010] In a third aspect, the present invention provides a solid powder composition comprising particles coated with a hydrophobic material, the coated particles comprising particles comprising nitrite and a proton source, the particles being coated with a hydrophobic material.

[0011] In this way, the coated particles contain the nitrite and the proton source within the same coating.

[0012] In a fourth aspect, the present invention provides a pharmaceutical composition comprising a solid powder composition of the first, second or third aspect and optionally one or more additives and / or adjuvants.

[0013] In a fifth aspect, the present invention provides a method of producing a solid powder composition comprising the steps of removing the solvent in less than 30 seconds (e.g. by spray drying) after mixing a nitrite solution and a proton source solution to provide a solid, and / or providing reaction delay conditions (e.g. freeze-drying) during solvent removal and before, during and / or immediately after mixing the nitrite solution and the proton source solution.

[0014] In a sixth aspect, the present invention provides a method of making a solid powder composition comprising particles coated with a hydrophobic material, comprising coating particles comprising nitrite and a proton source with a hydrophobic material.

[0015] In a seventh aspect, the present invention provides a solid powder composition of the first, second or third aspect or a pharmaceutical composition of the fourth aspect for use in a method of treating or preventing a respiratory disease or disorder.

[0016] In an eighth aspect, the present invention provides a method of treating or preventing a respiratory disease or disorder comprising administration of a therapeutically effective amount of a solid powder composition of the first, second or third aspect, or a pharmaceutical composition of the fourth aspect.

[0017] In a ninth aspect, the present invention provides a material comprising a substrate and the solid powder composition of the first, second or third aspect, wherein particles of the solid powder composition are incorporated or encapsulated in the substrate.

[0018] In a tenth aspect, the present invention provides a method of incorporating or encapsulating a solid powder composition of the first or second aspect in a substrate, the method comprising the steps of mixing the solid powder composition of the first, second or third aspect with a non-aqueous or non-polar liquid comprising a substrate or a substrate precursor to form a liquid-particle mixture, and (ii) solidifying the liquid-particle mixture to form a material incorporating or encapsulating the solid powder composition of the first, second or third aspect.

[0019] In an eleventh aspect, the present invention provides a material or device comprising a substrate and a spray dried coating on an exterior surface of the substrate, the spray dried coating being formed by spray drying a mixture comprising a nitrite salt solution and a proton source solution.

[0020] In a twelfth aspect, the present invention provides a material or device comprising a substrate and a coating on an exterior surface of the substrate, the coating being a homogenous solid comprising nitrite and a proton source.

[0021] In a thirteenth aspect, the present invention provides a method of providing a material or device comprising the step of spray drying a mixture comprising a nitrite solution and a proton source solution onto an external surface of a substrate to provide the material or device.

[0022] In a fourteenth aspect, the present invention provides a method of implanting a substance or device of the twelfth or thirteenth aspects into the human or animal body. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] Detailed Description The invention will now be described in further detail. The Examples and the following Figures provide illustrations of the invention. [Brief description of the drawings]

[0024] [Figure 1]FIG. 1 shows the deposition patterns of powders of Examples 1A and 2 on agarose using Hank's balanced salt solution and a pH indicator (phenol red).

[0025] [Diagram 2] 1 shows cumulative NO production for Examples 1A and 2.

[0026] [Diagram 3] 4 shows the sprouting intensity of HUVEC spheroids treated with Examples 1B and 4A as quantified by an image analysis system to determine cumulative sprout length (CSL) per spheroid compared to basal controls.

[0027] [Figure 4] 1 shows an SEM image of a spray dried powder described herein.

[0028] [Diagram 5] 1 shows an EDX analysis of the spray dried powder described herein.

[0029] [Figure 6] 1 shows EDX maps of nitrogen (green) versus backscattered electron image (BSE) and nitrogen versus carbon (blue) at 2000x microscope magnification for a spray dried powder described herein.

[0030] The reaction between one or more nitrites and a proton source to produce nitric oxide, optionally other nitrogen oxides and / or optionally their precursors, is referred to herein as the "NOx producing reaction" or "reaction to produce NOx" or similar expressions, and "NOx" is used to refer to the products of the acidification of nitrites, particularly nitric oxide, other nitrogen oxides and their precursors, individually and in any combination. It is understood that each component of the NOx produced may be evolved as a gas or may go into solution in the reaction mixture or may first go into solution and then be evolved as a gas, or any combination thereof.

[0031] The term "about" is used herein to indicate that a numerical value is not strictly limited, and one of ordinary skill in the art will understand that the value may be extended above and below (as appropriate) the precise range consistent with the understanding of the numerical value by one of ordinary skill in the art. The term "about" may indicate values ​​up to ±10% of the numerical value.

[0032] Unless otherwise specified, particle sizes referred to herein refer to volume mean diameter (VMD).

[0033] solid powder composition The solid powder composition of the present invention comprises a nitrite salt and a proton source, in such a way that the solid powder composition can release nitric oxide upon exposure to an aqueous environment or atmospheric moisture through acidification of the nitrite salt.

[0034] Nitrite The selection of nitrite is not particularly limited. The nitrite can be selected from one or more alkali metal nitrites or alkaline metal nitrites. For example, the one or more nitrites can be selected from LiNO2, NaNO2, KNO2, RbNO2, CsNO2, FrNO2, AgNO2, Be(NO2)2, Mg(NO2)2, Ca(NO2)2, Sr(NO2)2, Mn(NO2)2, Ba(NO2)2, Ra(NO2)2 and any mixture thereof. The nitrite can be NaNO2 or KNO2. The nitrite can be NaNO2.

[0035] The nitrite may be a pharmaceutically acceptable grade nitrite.In other words, the nitrite may comply with one or more valid pharmacopoeia monographs for nitrite.For example, the nitrite may comply with one or more monographs of the United States Pharmacopoeia (USP), the European Pharmacopoeia, or the Japanese Pharmacopoeia.

[0036] In particular, the nitrite used may have one or more of the characteristics provided in paragraphs

[0032] to

[0060] and / or Table 1 in paragraph

[0204] of WO2010 / 093746, the disclosure of which is incorporated herein by reference in its entirety.

[0037] Proton Source The proton source is any species that can act as a proton source for the acidification of nitrite. The choice of the proton source is not particularly limited. The proton source can be, for example, an acid.

[0038] The acid may be selected from one or more organic carboxylic acids or organic non-carboxylic reducing acids.

[0039] The expression "organic carboxylic acid" as used herein refers to any organic acid containing one or more -COOH groups in the molecule. The organic carboxylic acid may be straight or branched chain. The carboxylic acid may be saturated or unsaturated. The carboxylic acid may be aliphatic or aromatic. The carboxylic acid may be acyclic or cyclic. The carboxylic acid may be a vinylogous carboxylic acid.

[0040] The organic carboxylic acid may bear one or more substituents, such as one or more hydroxyl groups. Examples of hydroxyl-substituted organic carboxylic acids that may be used in the present invention include α-hydroxy-carboxylic acids, β-hydroxy-carboxylic acids and γ-hydroxy-carboxylic acids.

[0041] The expression "organic non-carboxylic reducing acid" as used herein refers to any organic reducing acid that does not contain a -COOH group in the molecule. The organic non-carboxylic reducing acid may be straight-chain or branched-chain. The non-carboxylic reducing acid may be saturated or unsaturated. The non-carboxylic reducing acid may be aliphatic or aromatic. The non-carboxylic reducing acid may be acyclic or cyclic. The non-carboxylic reducing acid may be vinylic.

[0042] The organic non-carboxylic reducing acid may bear one or more substituents, such as one or more hydroxyl groups. Examples of hydroxyl-substituted organic non-carboxylic reducing acids that may be used in the present invention include acidic reductones, such as reducing acid (2.3-dihydroxy-2-cyclopentanone).

[0043] The one or more organic carboxylic acids or non-carboxylic reducing acids may have a pKa of less than about 7.

[0044] The one or more organic carboxylic acids may comprise, consist of or be one or more reduced carboxylic acids.The organic carboxylic acid may be selected from, for example, salicylic acid, acetylsalicylic acid, acetic acid, citric acid, glycolic acid, mandelic acid, tartaric acid, lactic acid, maleic acid, malic acid, benzoic acid, formic acid, propionic acid, α-hydroxypropanoic acid, β-hydroxypropanoic acid, β-hydroxybutyric acid, β-hydroxy-β-butyric acid, naphthoic acid, oleic acid, palmitic acid, pamoic (embonic) acid, stearic acid, malonic acid, succinic acid, fumaric acid, glucoheptonic acid, glucuronic acid, lactobionic acid, cinnamic acid, pyruvic acid, orotic acid, glyceric acid, glycyrrhizic acid, sorbic acid, hyaluronic acid, alginic acid, oxalic acid, its salts and combinations thereof.

[0045] The organic carboxylic acid may be citric acid or a salt thereof.

[0046] The carboxylic acid may be or include a polymeric or polymerized carboxylic acid, such as, for example, polyacrylic acid, polymethacrylic acid, copolymers of acrylic acid and methacrylic acid, polylactic acid, polyglycolic acid, or copolymers of lactic acid and glycolic acid. Also encompasses partial or full esters of organic carboxylic acids or partial or full salts thereof, so long as they serve as a proton source in the uses of the present invention.

[0047] The organic non-carboxylic reducing acid may be selected from, for example, ascorbic acid; ascorbic acid palmitate (ascorbyl palmitate); ascorbic acid derivatives such as 3-O-ethyl ascorbic acid, other 3-alkyl ascorbic acids, 6-O-octanoyl ascorbic acid, 6-O-dodecanoyl ascorbic acid, 6-O-tetradecanoyl ascorbic acid, 6-O-octadecanoyl ascorbic acid, and 6-O-dodecandioyl ascorbic acid; acidic reductones such as reducing acids; erythorbic acid; salts thereof; and combinations thereof.

[0048] The organic non-carboxylic reducing acid can be ascorbic acid or a salt thereof.

[0049] The proton source may be one or more organic carboxylic acids or organic non-carboxylic reducing acids, suitably with their conjugate bases. The acids and their conjugate bases may suitably form buffer solutions when in contact with or exposed to an aqueous environment. The acids and their conjugate bases may be provided in a ratio that achieves a desired pH when exposed to an aqueous environment.

[0050] The buffer system may be selected to achieve and maintain a desired pH for the NOx producing reaction to proceed upon exposure to an aqueous environment. The buffer system may be selected such that the pH of the reaction may range from about 3 to 9, such as about 4 to 8. For physiological contact or contact with living cells and organisms, the pH of the reaction may range from about 5 to about 8. The conjugate base, when present, may be added separately or may be generated in situ from a proton source by adjusting the pH through the use of acids and / or bases, such as inorganic acids and / or inorganic bases.

[0051] The proton source can be a citric acid / citric acid buffer system, for example, and a citric acid / trisodium citrate buffer system.

[0052] It will be appreciated by those skilled in the art that the choice of acid component / proton source may be selected depending on the desired use of the solid powder composition.

[0053] Particles in a solid powder composition The solid powder composition may comprise particles that contain both nitrite and a proton source. In other words, the solid composition comprises particles, one or more of which contain a proton source and a nitrite within the same particle. In this way, the proton source component and the nitrite component may remain in close proximity even when the powder is dispersed (e.g., via inhalation of the powder).

[0054] The particles of the solid composition can have a particle size suitable for the desired use or application.For example, the particles of the solid composition can have a particle size of about 10 μm or less, for example, about 5 μm or less, about 4 μm or less, about 3 μm or less, about 2 μm or less, or about 1 μm or less.

[0055] Alternatively, the particles of the solid composition may have a particle size of 5 μm. For example, the particles of the solid composition may have a particle size of more than 50 μm, more than 100 μm, more than 250 μm, more than 500 μm, more than 750 μm, more than 1000 μm.

[0056] The weight ratio of nitrite:proton source in the solid composition can be in the range of about 1:1 to about 1:99, such as about 1:4 to about 1:49 or about 1:7 to about 1:24.

[0057] The solid powder composition may contain further optional additives such as a binder or an organic polyol.

[0058] Binder The solid powder composition may be substantially free of one or more binders. Alternatively, the solid powder composition may further comprise one or more binders. As used herein, "binder" refers to an agent that promotes adhesion of particles.

[0059] Suitable binders may include sugars, natural binders, or synthetic or semi-synthetic polymeric binders. Sugar species may include, for example, sucrose or liquid glucose. Natural binders may include, for example, acacia, tragacanth, gelatin, starch paste, pregelatinized starch, alginic acid, or cellulose. Synthetic or semi-synthetic polymeric binders may include, for example, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polyvinyl alcohol, polymethacrylic acid. Binders may be copolymers of 1-vinyl-2-pyrrolidone and vinyl acetate (copovidone). Binders may be microcrystalline cellulose.

[0060] The binder may be incorporated into the composition at a % w / w of about 5% w / w to about 30% w / w. For example, the binder may be incorporated into the composition at a % w / w of about 10% w / w to about 25% w / w.

[0061] Organic Polyol The solid powder composition may be substantially free of one or more organic polyols. Alternatively, the solid powder composition may further comprise one or more organic polyols. When the solid powder composition comprises one or more organic polyols, it is preferred that the organic polyols are added to the composition after any process involving solvent removal (e.g., after a spray-drying or freeze-drying process). In other words, the polyols may be added to the composition comprising one or more particles comprising nitrite and a proton source.

[0062] The expression "organic polyol" as used herein refers specifically to an organic molecule having two or more hydroxyl groups that is not a source of protons for the nitrite reaction and is not a saccharide or polysaccharide (the terms "saccharide" and "polysaccharide" include oligosaccharides, glycans and glycosaminoglycans). Organic polyols therefore have a pKa of about 7 or greater.

[0063] The expression "organic polyol" here preferably excludes reducing agents. Examples of reducing agents that are organic molecules with two or more hydroxyl groups and are not saccharides or polysaccharides are thioglycerol (e.g. 1-thioglycerol), hydroquinone, butylated hydroquinone, ascorbic acid, ascorbate, erythorbic acid and erythorbate. Thioglycerol (e.g. 1-thioglycerol), hydroquinone, butylated hydroquinone, ascorbate and erythorbate are therefore preferably excluded from the expression "organic polyol" since they are reducing agents. Ascorbic acid and erythorbic acid are in any case excluded from this expression since they are proton sources, especially for the nitrite reaction.

[0064] The organic polyol may be cyclic or acyclic, or may be a mixture of one or more cyclic organic polyols and one or more acyclic organic polyols.For example, the one or more organic polyols may be selected from one or more alkanes substituted with two or more OH groups, one or more cycloalkanes substituted with two or more OH groups, one or more cycloalkylalkanes substituted with two or more OH groups, and any combination thereof.The organic polyol may not carry any substituents other than OH.

[0065] The one or more organic polyols may be one or more acyclic organic polyols. The one or more acyclic organic polyols may be selected from sugar alcohols having 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. The one or more acyclic organic polyols may be selected from alditols, such as alditols having 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. The one or more organic polyols may not include saponins, sapogenins, steroids or steroidal glycosides.

[0066] Alternatively, the one or more organic polyols can be one or more cyclic organic polyols. The one or more cyclic organic polyols can be cyclic sugar alcohols or cyclic alditols. For example, the one or more cyclic polyols can be cyclic sugar alcohols having 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms or cyclic alditols having 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. A specific example of a cyclic polyol is inositol.

[0067] The one or more organic polyols may have 7 or more hydroxyl groups. The one or more organic polyols may be sugar alcohols or alditols having 7 or more hydroxyl groups. The one or more organic polyols may have 9 or more hydroxyl groups. The one or more organic polyols may be sugar alcohols or alditols having 9 or more hydroxyl groups. The one or more organic polyols may have 20 or less hydroxyl groups. The one or more organic polyols may be sugar alcohols or alditols having 20 or less hydroxyl groups. The one or more organic polyols may have 15 or less hydroxyl groups. The one or more organic polyols may be sugar alcohols or alditols having 15 or less hydroxyl groups. The one or more organic polyols may have a number of hydroxyl groups in the range of 7 to 20, for example in the range of 9 to 15. The one or more organic polyols may include 9, 12, 15 or 18 hydroxyl groups.

[0068] The one or more organic polyols may be sugar alcohol compounds that include, e.g., consist of, one or more monosaccharide units and one or more acyclic sugar alcohol units. The one or more organic polyols may be sugar alcohol compounds that include, e.g., consist of, linear chains of one or more monosaccharide units and one or more acyclic sugar alcohol units or branched chains of one or more monosaccharide units and one or more acyclic sugar alcohol units.

[0069] As used herein, a "monosaccharide unit" refers to a monosaccharide that is covalently bound to at least one other unit in the compound (either another monosaccharide unit or an acyclic sugar alcohol unit). As used herein, an "acyclic sugar alcohol unit" refers to an acyclic sugar alcohol that is covalently bound to at least one other unit in the compound (either another monosaccharide unit or another acyclic sugar alcohol unit). The units in the compound may be linked via ether bonds. One or more of the monosaccharide units may be covalently bound to other units in the compound via glycosidic bonds. Each of the monosaccharide units may be covalently bound to other units in the compound via glycosidic bonds. The sugar alcohol compound may be a glycoside having a monosaccharide or oligosaccharide glycone and an acyclic sugar alcohol aglycone.

[0070] The acyclic sugar alcohol unit may be a sugar alcohol unit having 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. The acyclic sugar alcohol unit may be selected from the group consisting of erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol and volemitol units.

[0071] One or more of the monosaccharide units can be a C5 or C6 monosaccharide unit, i.e., a pentose or hexose unit. Each monosaccharide unit can be a C5 or C6 monosaccharide unit. One or more of the sugar alcohol units can be a C5 or C6 sugar alcohol unit. Each sugar alcohol unit can be a C5 or C6 sugar alcohol unit.

[0072] A sugar alcohol compound may comprise, e.g., consist of, n monosaccharide units and m acyclic sugar alcohol units, where n is an integer and is at least 1, m is an integer and is at least 1, and (n+m) does not exceed 10. A sugar alcohol compound may comprise, e.g., consist of, a chain of n monosaccharide units terminating in one acyclic sugar alcohol unit, where n is an integer from 1 to 9. The chain of monosaccharide units may be covalently linked by glycosidic bonds. Each monosaccharide unit may be covalently linked to other monosaccharide units or to acyclic sugar alcohol units by glycosidic bonds. A sugar alcohol compound may comprise, e.g., consist of, a chain of one, two or three monosaccharide units terminating in one acyclic alcohol unit. The one, two, three or each monosaccharide unit may be a C5 or C6 monosaccharide unit. The acyclic alcohol unit may be a C5 or C6 sugar alcohol unit. Examples of sugar alcohol compounds include, but are not limited to, isomalt, maltitol and lactitol (n=1); maltotriitol (n=2); and maltotetraitol (n=3).

[0073] Such sugar alcohol compounds may be described as sugar alcohols derived from disaccharides. As used herein, "oligosaccharide" refers to a saccharide consisting of 3 to 10 monosaccharide units. Disaccharide- or oligosaccharide-derived sugar alcohols may be synthesized (e.g., by hydrolysis and hydrogenation) from disaccharides, oligosaccharides, or polysaccharides, but are not limited to compounds synthesized from disaccharides, oligosaccharides, or polysaccharides. For example, disaccharide-derived sugar alcohols may be formed by dehydration of monosaccharides and sugar alcohols. The one or more organic polyols may be sugar alcohols derived from disaccharides, trisaccharides, or tetrasaccharides. Examples of sugar alcohols derived from disaccharides include, but are not limited to, isomalt, maltitol, and lactitol. Examples of sugar alcohols derived from trisaccharides include, but are not limited to, maltotriitol. Examples of sugar alcohols derived from tetrasaccharides include, but are not limited to, maltotetraitol.

[0074] The organic polyol may be selected from erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, polyglycitol, and any combination thereof. Glycerol may be used together with one or more other organic polyols, such as erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, polyglycitol, or any combination thereof, and when present, is preferably together.

[0075] Many organic polyols contain one or more chiral centers and therefore exist in stereoisomeric forms.All stereoisomeric forms and optical isomers of organic polyols and isomeric mixtures are intended to be included within the scope of the present invention.In particular, the D and / or L forms of all chiral organic polyols and all mixtures thereof may be used.

[0076] Coated particles The solid powder composition may include particles coated with a hydrophobic material (also referred to herein as coated particles).

[0077] The coated particles may include a single particle that includes a nitrite salt and a proton source, and is coated with a hydrophobic material.

[0078] In this way, the coated particles contain the nitrite and the proton source within the same coating.

[0079] The hydrophobic material may be any material capable of coating the particles such that the particles are covered with a hydrophobic layer. The hydrophobic material may be a polymeric material, such as an organic polymeric material. The hydrophobic material may be an amphiphilic species, such as a surfactant-type species, such as a nonionic, anionic, cationic or amphoteric surfactant-type species. The hydrophobic material may be an inorganic mineral material, such as an inorganic mineral material that forms a 3D framework. The hydrophobic material may be biocompatible. The hydrophobic material may include one or more of poly(lactic-co-glycolic acid) (PLGA), dipalmitoyl phosphatidylcholine (DPPC), magnesium stearate and mesoporous silica. The hydrophobic material may include the polymeric material poly(lactic-co-glycolic acid) (PLGA) without acid end groups or with acid end groups.

[0080] As used herein, "surfactant" refers to a surfactant capable of reducing the surface tension of a species in a medium or the interfacial tension between media. Surfactant species generally have a hydrophilic head and a hydrophobic tail.

[0081] The hydrophobic material may be attached to the particle by chemical bonds or by electrostatic or intermolecular forces.

[0082] The coating of the coated particles can affect the reaction kinetics, eg, reaction kinetics, of the acidification of nitrite when the coated particles are exposed to an aqueous environment.

[0083] The particles of the coated solid composition can have a suitable particle size for the desired use or application. The particles of the coated solid composition can have a particle size of about 10 μm or less, for example, about 5 μm or less, about 4 μm or less, about 3 μm or less, about 2 μm or less, or about 1 μm or less. Alternatively, the particles of the coated solid composition can have a particle size of more than about 5 μm. For example, the particles of the solid composition can have a particle size of more than about 50 μm, more than about 100 μm, more than about 250 μm, more than about 500 μm, more than about 750 μm, or more than about 1000 μm.

[0084] Particle formation from mixtures containing nitrite and proton source solutions Particles of the solid powder composition may be formed from a mixture containing a nitrite solution and a proton source solution. The particles thus formed should be formed by removing the solvent for a short time (e.g., 30 seconds or less) after mixing the nitrite solution with the proton source solution and / or by placing the mixture under reaction delay conditions (e.g., a temperature below the freezing point of the solvent) after mixing the nitrite solution with the proton source solution and for solvent removal. In this manner, the solvent is removed from the mixture while minimizing acidification of the nitrite. Effective amounts of nitrite and proton source may therefore be present in the resulting powder composition.

[0085] When the solvent is removed a short time after mixing the nitrite solution and the proton source solution, the solvent may be removed 30 seconds or less after mixing the nitrite solution and the proton source solution. In some examples, the solvent is removed 10 seconds or less, 5 seconds or less, 2 seconds or less, or 1 second or less after mixing the nitrite solution and the proton source solution. In some examples, the solvent is removed 500 milliseconds or less, 100 milliseconds or less, 50 milliseconds or less, or 10 milliseconds or less after mixing the nitrite solution and the proton source solution.

[0086] In some instances, the particles may be formed by spray drying a mixture comprising a nitrite solution and a proton source solution. Spray drying the mixture may allow for removal of the solvent in a time period of 30 seconds or less after mixing of the nitrite solution and the proton source solution. Spray drying of materials is known per se.

[0087] The mixture is typically a mixture of an aqueous nitrite solution and an aqueous proton source solution. When an aqueous solution is used, the time between mixing of the two aqueous solutions is minimized to inhibit acidification of the nitrite. The aqueous nitrite solution and the aqueous acid solution may be mixed in-line for about 1 to about 10 milliseconds, for example about 3 to about 5 milliseconds, before performing spray drying. Spray drying may be performed immediately after mixing of the nitrite solution and the acid solution. It is understood that mixing and spray drying of a mixture containing the described nitrite solution and proton source solution limits the potential reaction time between the proton source and nitrite components.

[0088] The particles formed by spray drying the mixture including the nitrite solution and the acid solution may have a particle size of about 10 μm or less, e.g., about 5 μm or less, about 4 μm or less, about 3 μm or less, about 2 μm or less, or about 1 μm or less.

[0089] Spray drying of a mixture including the described nitrite and acid solutions can result in a solid powder composition, with each particle including a nitrite component and a proton source component.

[0090] The particles formed by spray drying a mixture comprising a nitrite solution and a proton source solution can be in any suitable form. For example, the particles formed by spray drying a mixture comprising a nitrite solution and a proton source solution can be in a crystalline form or an amorphous form. The particles formed by spray drying a mixture comprising a nitrite solution and a proton source solution can be in an amorphous form.

[0091] Additionally or alternatively, the mixture of the nitrite and proton source solutions is placed under reaction delay conditions (e.g., at a temperature below the freezing point of the solvent) before, during or immediately after mixing the nitrite and proton source solutions and for solvent removal. In this manner, acidification of the nitrite is delayed until the solvent is removed. In particular, the solvent may be an aqueous solvent.

[0092] A specific example of a reaction delay condition is a temperature of the mixture below the freezing point of the solvent. In this way, the reaction rate of the acidification of the nitrite can be delayed while the solvent is removed. When the temperature of the mixture is below the freezing point of the solvent, the nitrite solution and the proton source solution are typically mixed at a temperature above the freezing point of the solvent before the temperature of the mixture is reduced to the freezing point of the solvent. In this way, good mixing of the solutions can occur.

[0093] In some instances, solvent removal may be performed at low gas pressures, particularly in combination with temperatures below the freezing point of the solvent being removed.

[0094] A particularly useful technique for solvent removal under reaction-retarding conditions is lyophilization (also called "freeze-drying").

[0095] It should be noted that the terms "solvent removal" and / or "drying" used herein are for the achievement of a solid powder composition. These terms include, but are not limited to, complete removal of the solvent. In some instances, the solid powder composition may contain trace amounts of residual solvent. For example, the powder composition may contain up to about 10% residual solvent, such as up to about 5% residual solvent, up to about 3% residual solvent, or up to about 1% residual solvent. Additional drying techniques, such as vacuum drying, may be used after the initial solvent removal to provide a solid powder composition.

[0096] Pharmaceutical Compositions The solid powder compositions disclosed herein can be included in pharmaceutical compositions, optionally together with one or more pharma- ceutically acceptable carriers, additives and / or adjuvants, which, when desired for in vivo use, can be physiologically compatible.

[0097] Physiologically compatible carriers and / or excipients, e.g., examples of carriers and / or excipients include, but are not limited to, lactose, starch, dicalcium phosphate, magnesium stearate, sodium saccharin, talc, cellulose, cellulose derivatives, croscarmellose sodium, glucose, gelatin, sucrose, magnesium carbonate, magnesium chloride, magnesium sulfate, calcium chloride, and the like.

[0098] Generally speaking, depending on the intended method of administration, the pharmaceutical composition will contain from about 0.005% to about 95%, preferably from about 0.5% to about 50%, by weight, of the combination or composition of the present invention or its components. Actual methods for preparing such dosage forms will be known or apparent to those skilled in the art.

[0099] The additives may be selected from known additives depending on the intended use or the route of administration of the reactant and / or the reactant product to be delivered to the target site for delivery of nitric oxide, optionally other nitrogen oxides and / or optionally precursors thereof. For example, creams, lotions and ointments may be formulated by incorporating nitrite into an additive such as a cream, lotion or ointment base or other thickening and thickening agent (e.g., Eudragit L100, carbopol, carboxymethylcellulose or hydroxymethylcellulose). A proton source may be incorporated into an additive selected from carbopol, carboxymethylcellulose, hydroxymethylcellulose, methylcellulose, ethanol, lactose or aqueous base. When it is desired to form a film, a film-forming additive may be used, such as, for example, propylene glycol, polyvinylpyrrolidone (povidone), gelatin, guar gum and shellac.

[0100] Optional additional ingredients can be selected from, for example, sweeteners, flavoring agents, thickeners, thickeners, wetting agents, lubricants, binders, film-forming agents, emulsifiers, solubilizers, stabilizers, colorants, odorants, salts, coating agents, antioxidants, pharma-ceutical active agents, and preservatives. Such ingredients are well known in the art, and detailed descriptions thereof are unnecessary for those skilled in the art. Examples of wetting agents, emulsifiers, lubricants, binders, and solubilizers include, for example, sodium phosphate, potassium phosphate, gum acacia, polyvinylpyrrolidone, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like. Sweeteners or flavoring agents may include sugars, saccharin, aspartame, sucralose, neotame, or other compounds that beneficially affect, for example, taste, aftertaste, perceived unpleasant saltiness, sourness, or bitterness, to reduce the tendency of the oral or inhaled formulation to irritate the recipient (e.g., by causing coughing or sore throat or other undesirable side effects, which may, for example, reduce the delivered dose or adversely affect patient compliance with the prescribed treatment regimen). Certain flavoring agents may form complexes with one or more of the nitrites. Examples of thickening agents, viscosity enhancing agents, and film formers are provided above.

[0101] Examples of pharma- ceutical active agents that may be incorporated or co-administered in the components and compositions of the invention include antibiotics, steroids, anesthetics (e.g., local anesthetics such as lignocaine (lidocaine), amethocaine (tetracaine), xylocaine, bupivacaine, prilocaine, ropivacaine, benzocaine, mepivacaine, cocaine, or any combination thereof), analgesics, anti-inflammatories (e.g., nonsteroidal anti-inflammatory drugs (NSAIDs)), anti-infectives, vaccines, immunosuppressants, anticonvulsants, anti-dementia drugs, prostaglandins, antipyretics, anticycotics, antipsoriatics, antivirals, vasodilators or vasoconstrictors, sunscreens (e.g., PABA), antihistamines, estrogens, progesterone, or androgens. The active ingredient in the composition includes hormonal agents such as rheumatoid arthritis drugs, antiseborrheic agents, cardiovascular treatments such as alpha or beta blockers or Rogaine, vitamins, emollients, enzymes, mast cell stabilizers, scabicides, pediculicides, keratolytic agents, lubricants, anesthetics, shampoos, anti-acne preparations, burn treatment preparations, cleansers, deodorants, bleaching agents, diaper rash treatment products, emollients, moisturizers, photosensitizers, poison ivy or sumac or poison oak products, sunburn treatment preparations, proteins, peptides, proteoglycans, nucleotides, oligonucleotides (e.g., DNA, RNA, etc.), minerals, growth factors, tar-containing preparations, honey-containing preparations (e.g., manuka honey-containing preparations), wart treatment preparations, compresses, wound care products, or any combination thereof.

[0102] Specific examples include analgesics such as ibuprofen, indomethacin, diclofenac, acetylsalicylic acid, paracetamol, propranolol, metoprolol and oxycodone; thyroid releasing hormone; sex hormones such as estrogen, progesterone and testosterone; insulin; verapamil; vasopressin; hydrocortisone; scopolamine; nitroglycerin; isosorbide dinitrate; antihistamines such as terfenadine; clonidine; nicotine; nonsteroidal immunosuppressants such as cyclosporine, methotrexate, azathioprine, mycophenolate, cyclophosphamide, TNF-α antagonists and anti-IL5, anti-IL4Ra, anti-IL6, anti-IL13, anti-IL17, anti-IL23 cytokine monoclonal antibodies; anticonvulsants; and drugs for Alzheimer's, dementia and / or Parkinson's disease such as apamorphine and rivastigmine.

[0103] If optional additives are added to the pharmaceutical compositions, including the solid powder compositions disclosed herein, these optional additives may be in a solid state, e.g., in dry particulate form.

[0104] Method for Producing a Solid Powder Composition Method for Producing Solid Powder Compositions by Solvent Removal A method of producing a solid powder composition may include removing the solvent from a mixture of a nitrite solution and a proton source solution in a manner that minimizes acidification prior to forming the powder composition.

[0105] In certain instances, the method includes the step of removing the solvent (eg, by spray drying) in less than 30 seconds after combining the nitrite solution and the proton source solution to form a solid.

[0106] In other examples, the method includes providing reaction delay conditions (eg, lyophilization) during mixing of the nitrite solution and the proton source solution and / or immediate solvent removal.

[0107] In certain instances, the method may include the step of removing the solvent from an aqueous mixture including a nitrite salt solution and a proton source solution to form a solid powder.

[0108] The aqueous nitrite solution may have a concentration ranging from about 0.1 M to about 5 M. The aqueous nitrite solution may have a concentration of at least about 0.1 M, at least about 0.2 M, at least about 0.5 M, at least about 0.75 M, or at least about 1 M. The aqueous nitrite solution may have a concentration up to about 5 M, up to about 4 M, up to about 3 M, or up to about 2 M. For example, the aqueous nitrite solution may have a concentration ranging from about 1 M to about 2 M, e.g., about 1.5 M. The aqueous nitrite solution may have a pH of about 6.5 to about 9, e.g., about 7 to about 8.

[0109] The aqueous proton source solution may have a concentration ranging from about 0.1M to about 5M. The aqueous nitrite solution may have a concentration of at least about 0.1M, at least about 0.2M, at least about 0.5M, at least about 0.75M, or at least about 1M. The aqueous nitrite solution may have a concentration of up to about 5M, up to about 4M, up to about 3M, or up to about 2M. For example, the aqueous nitrite solution may have a concentration ranging from about 0.5M to about 1.5M, e.g., about 1M. The aqueous citric acid solution may have a pH of about 4 to 6. The pH of the aqueous proton source solution may be adjusted using an inorganic base, e.g., sodium hydroxide.

[0110] In some instances, the step of removing the solvent takes 20 seconds or less, 10 seconds or less, 5 seconds or less, 2 seconds or less, or 1 second or less after mixing the nitrite solution and the proton source solution, hi some instances, the solvent is removed 500 milliseconds or less, 100 milliseconds or less, 50 milliseconds or less, or 10 milliseconds or less after mixing the nitrite solution and the proton source solution.

[0111] spray drying A solid powder composition may be produced by spray drying a solution of the nitrite salt and a solution of a proton source.

[0112] The aqueous nitrite and acid solutions may be mixed in-line for about 1 to about 10 milliseconds, e.g., about 3 to about 5 milliseconds, prior to performing spray drying. Spray drying may be performed immediately after mixing the nitrite and proton source solutions. It will be appreciated that the mixing and spray drying of a mixture comprising the described nitrite and proton source solutions greatly limits the possibility of reaction between the proton source and the nitrite components, and that rapid removal of moisture will halt any reaction.

[0113] Spray drying may be carried out at an outlet temperature in the range of about 60 to about 80° C., such as about 65 to about 75° C. or about 68 to about 70° C. Spray drying may be carried out at an atomization pressure in the range of about 1 to 6 bar. Spray drying may be carried out at a liquid feed rate in the range of about 1 to about 5 g / min, such as about 2 g / min to about 4 g / min or about 3 g / min.

[0114] Response delay conditions Alternatively, the method may include providing reaction delay conditions (eg, lyophilization) during solvent removal and before, during and / or immediately after mixing of the nitrite solution and the proton source solution.

[0115] A specific example of a reaction delay condition is a temperature of the mixture below the freezing point of the solvent. In this way, the reaction rate of the acidification of the nitrite can be delayed while the solvent is removed. When the temperature of the mixture is below the freezing point of the solvent, the nitrite solution and the proton source solution are typically mixed at a temperature above the freezing point of the solvent before the temperature of the mixture is reduced to the freezing point of the solvent. In this way, good mixing of the solutions can occur.

[0116] In some instances, solvent removal may be performed at low gas pressures, particularly in combination with temperatures below the freezing point of the solvent being removed.

[0117] A particularly useful technique for solvent removal under reaction-retarding conditions is lyophilization (also called "freeze-drying").

[0118] The time required for solvent removal after mixing of the nitrite solution and the proton source solution under delayed reaction conditions may be about 10 minutes or less. Under these conditions, such rapid removal of the solvent (e.g., water) may not be important. However, removal of the solvent in a relatively short time frame may also be desired to further limit the acidification of the nitrite. In some examples, the solvent is removed in about 8 minutes or less, e.g., about 7 minutes or less, about 6 minutes or less, about 5 minutes or less, about 4 minutes or less, about 3 minutes or less, or about 2 minutes or less under delayed reaction conditions after mixing of the nitrite solution and the proton source solution. In further examples, the step of solvent removal requires about 1 minute or less, about 30 seconds or less, about 20 seconds or less, about 15 seconds or less, or about 10 seconds or less after mixing of the nitrite solution and the proton source solution.

[0119] It should be noted that the terms "solvent removal" and / or "drying" used herein are for the achievement of a solid powder composition. These terms include, but are not limited to, complete removal of the solvent. In some instances, the solid powder composition may contain trace amounts of residual solvent. For example, the powder composition may contain up to about 10% residual solvent, such as up to about 5% residual solvent, up to about 3% residual solvent, or up to about 1% residual solvent. Additional drying techniques, such as vacuum drying, may be used after the initial solvent removal to provide a solid powder composition.

[0120] Method for Producing a Solid Powder Composition Having Coated Particles - Patent application A solid powder composition comprising particles coated with a hydrophobic material may be produced. The method may comprise the step of coating particles comprising nitrite and a proton source with a hydrophobic material.

[0121] The hydrophobic material can be the same hydrophobic material described above.

[0122] The particles may be coated by any suitable method known to those skilled in the art.

[0123] The particles may be coated by dispersing the particles in a solution containing a hydrophobic material and drying the solution to provide the particles coated with a layer of the hydrophobic material. In some instances, the solution contains a non-polar solvent. In particular, the solution does not contain a polar solvent (e.g., methanol). Such a polar solvent may dissolve at least a portion of the particles. In particular, the solution may be aqueous-free.

[0124] The hydrophobic material can be, for example, PLGA. The particles can be dried with the hydrophobic material in a 1:1 w / w ratio. The solution in which the particles are dissolved or suspended can be a solution of DCM and the hydrophobic material.

[0125] In a specific embodiment, the suspension of particles in the hydrophobic material solution is dried by spray drying. The solution containing the hydrophobic material in which the particles are dispersed can be spray dried at an outlet temperature of about 28-30°C. The solution containing the hydrophobic material in which the particles are dispersed can be spray dried at an atomization pressure of about 1 bar. The solution containing the hydrophobic material in which the particles are dispersed can be spray dried at a liquid feed rate of about 2 g / min.

[0126] The coated particles may have a particle size of less than about 10 μm, such as less than about 9 μm, such as less than about 8 μm, less than about 7 μm, less than about 6 μm or less than about 5 μm.

[0127] The particles can be coated by mixing the particles with a hydrophobic material to provide the particles coated with a layer of the hydrophobic material. The hydrophobic material can be, for example, DPPC, magnesium stearate, mesoporous silica, or a combination thereof. The particles can be mixed with the hydrophobic material in a 1:1 w / w ratio. The hydrophobic material can be sieved before mixing. Alternatively, the hydrophobic material can be not sieved before mixing.

[0128] The particles may be mixed with the hydrophobic material for about 10 to about 40 minutes, or for about 15 to about 30 minutes.

[0129] aqueous environment The solid powder composition of the present invention typically releases NOx when contacted with an aqueous environment, which is not particularly limited.

[0130] The aqueous environment can be an aqueous biological fluid, such as a bodily fluid. Such bodily fluids can include wound exudates, airway surface liquids (e.g., respiratory mucus) and / or blood (e.g., plasma, serum).

[0131] Alternatively, the aqueous environment can be a sterile aqueous solution. The aqueous environment can be a saline solution.

[0132] In some embodiments, the solid powder composition may be sufficiently hygroscopic to absorb moisture from the air, which is sufficient to initiate the emission of NOx.

[0133] Methods of treatment or prevention Methods for treating or preventing respiratory diseases or disorders The present invention includes a method of treating or preventing a respiratory disease or disorder comprising administering a therapeutically effective amount of a solid powder composition or pharmaceutical composition disclosed herein.

[0134] The present invention further provides a solid powder composition or pharmaceutical composition disclosed herein for use in a method of treating or preventing a respiratory disease or disorder.

[0135] The particles of the solid composition or pharmaceutical composition can have a particle size suitable for deep lung inhalation and respiratory application.The particles in the solid powder composition can have an average particle size of 10 microns or less when used for treating or preventing respiratory diseases or disorders.For example, the particles of the solid composition or pharmaceutical composition can have a particle size of about 10 μm or less, for example, about 5 μm or less, about 4 μm or less, about 3 μm or less, about 2 μm or less, or about 1 μm or less.

[0136] Conditions treatable using the present invention may include, for example, viral infections such as influenza, SARS-CoV or SARS-CoV-2, pulmonary arterial hypertension, ischemia-reperfusion injury of the heart, brain and organs involved in transplantation, chronic obstructive pulmonary disease (COPD) (particularly emphysema, chronic bronchitis), asthma, including severe asthma and viral and bacterial induced exacerbations of asthma and refractory (irreversible) asthma, intranasal or pulmonary bacterial infections, such as pneumonia, tuberculosis, nontuberculous mycobacteriosis and other bacterial and viral pulmonary infections, such as secondary bacterial infections following viral infection of the respiratory tract.

[0137] The property of nitric oxide to induce vasodilation characterizes some of the treatments that employ the solid powder or pharmaceutical compositions of the present invention and the NOx gas generated therefrom.

[0138] Particular examples of diseases, disorders and conditions responsive to vasodilation include, but are not limited to, conditions associated with ischemia.

[0139] Conditions associated with tissue ischemia include Raynaud's syndrome, severe primary vasospasm and tissue ischemia due to, for example, surgery, septic shock, radiation or peripheral vascular disease (eg diabetes and other chronic systemic diseases).

[0140] In some embodiments, respiratory disease or disorder may be associated with the presence of one or more microorganisms in the subject to be treated.In other words, respiratory disease or disorder may be associated with one or more microbial infections in the subject.When exposed to an aqueous environment, the NOx gas generated from the solid powder composition or pharmaceutical composition can potentially have biocidal or biostatic properties on a wide range of microorganisms, resulting in many antimicrobial treatments.The microorganism may be any one or more selected from bacterial cells, virus particles and / or fungal cells or parasitic microorganisms, and may be individual cells, organisms or colonies.

[0141] When the microorganism is present in a bacterial, fungal, viral or parasitic microbial infection in humans or other animals, the infection can be in the context of a disease such as the common cold, influenza, tuberculosis, SARS, COVID-19, pneumonia or measles.

[0142] The bacteria can be a pathogenic bacterial species. The microbial infection can be an infection caused by a pathogenic bacterial species, including gram-positive and gram-negative, aerobic and anaerobic, antibiotic-susceptible and antibiotic-resistant bacteria.

[0143] Examples of bacterial species that may be targeted using the present invention may include species of the genera Actinomyces, Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacterium, Mycoplasma, Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, or Yersinia. Any combination thereof may also be targeted by the present invention.

[0144] The microorganism may be a pathogenic species of the genera Corynebacterium, Mycobacterium, Streptococcus, Staphylococcus, Pseudomonas, or any combination thereof.

[0145] Targeted microorganisms include Actinomyces israelii, Bacillus anthracis, Bacteroides fragilis, Bordetella pertussis, Borrelia burgdorferi, Borrelia garinii; Borrelia afzelii; Borrelia recurrentis; Brucella abortus; Brucella canis; Brucella melitensis; Brucella suis; Campylobacter jejuni; Chlamydia pneumoniae; Chlamydia trachomatis; Chlamydophila psittaci; Clostridium botulinum; Clostridium purpurea; Trichoderma difficile;Clostridium perfringens;Clostridium tetani;Corynebacterium diphtheriae;Ehrlichia canis;Ehrlichia chaffeensis;Enterococcus faecalis;Enterococcus faecium;Escherichia coli, such as enterotoxigenic E. coli (ETEC) including E. coli O157:H7, enteropathogenic E. coli, invasive E. coli (EIEC) and enterohemorrhagic E. coli (EHEC);Francisella tularensis;Haemophilus influenzae;Helicobacter pylori; Helicobacter pylori;Klebsiella pneumoniae;Legionella pneumophila;Leptospira spp.;Listeria monocytogenes;Mycobacterium leprae;Mycobacterium tuberculosis;Mycobacterium abscessus;Mycobacterium ulcerans;Mycoplasma pneumoniae;Neisseria gonorrhoeae;Neisseria meningitides;Pseudomonas aeruginosa;Nocardia asteroides;Rickettsia rickettsii;Salmonella typhi ;Salmonella typhimurium;Shigella sonnei;Shigella dysenteriae;Staphylococcus aureus;Staphylococcus epidermidis;Staphylococcus saprophyticus;Streptococcus agalactiae;Streptococcus pneumoniae;Streptococcus pyogenes;Streptococcus viridans;Treponema pallidum subsp. pallidum;Vibrio cholerae;Yersinia pestis;and any combination thereof.

[0146] The microorganism may be selected from Chlamydia pneumoniae, Bacillus anthracis, Corynebacterium diphtheriae, Haemophilus influenzae, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium ulcerans, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, or any combination thereof.

[0147] The microorganism may be an antibiotic-resistant or antibiotic-sensitive pathogenic bacterial species or an antibiotic-resistant or antibiotic-sensitive strain of a bacterial species. The use of nitric oxide for the treatment of Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA) is described, for example, in WO02 / 20026, the disclosure of which is incorporated herein by reference. An example of an antibiotic-resistant or antibiotic-sensitive pathogenic bacterial species that can be killed or treated using the present invention is therefore Methicillin-resistant Staphylococcus aureus (MRSA) or Methicillin-sensitive Staphylococcus aureus (MSSA).

[0148] The microorganism may be a pathogenic fungal species. The microbial infection may be an infection caused by a pathogenic fungal species, including a pathogenic yeast.

[0149] Examples of fungal species that may be targeted using the present invention include Aspergillus, Blastomyces, Candida (e.g., Candida auris), Coccidioides, Cryptococcus (particularly Cryptococcus neoformans or Cryptococcus gattii), Histoplasma, Murcomycetes, Pneumocystis (e.g., Pneumocystis jirovecii), Sporothrix, Talaromyces species, or any combination thereof.

[0150] Examples of fungal infections include aspergillosis (e.g. allergic bronchopulmonary aspergillosis), tinea pedis (athlete's foot), infections caused by pathogenic species of Candida such as vaginal yeast infections, fungal toenail infections and diaper rash, jock itch and tinea corporis (ring rash).

[0151] The microorganism may be a virus particle. The infection may be caused by a pathogenic virus.

[0152] Examples of viruses that may be targeted using the present invention include influenza virus, parainfluenza virus, adenovirus, norovirus, rotavirus, rhinovirus, coronavirus, respiratory syncytial virus (RSV), astrovirus, and hepatic virus. The compositions of the present invention may be used to treat or prevent infection caused by one of the group selected from H1N1 influenza virus, infectious bovine rhinotracheitis virus, bovine respiratory syncytial virus, bovine parainfluenza-3 virus, SARS-CoV, SARS-CoV-2, and any combination thereof.

[0153] The present invention can be applied to treat diseases or disorders caused by viral infection.Examples of such diseases that the present invention can target include respiratory viral diseases, digestive viral diseases, exanthematous viral diseases, liver viral diseases, skin viral diseases, hemorrhagic viral diseases and neuroviral diseases.

[0154] Respiratory viral infections include influenza, rhinovirus (i.e. common cold virus), respiratory syncytial virus, adenovirus, coronavirus infections, e.g., COVID-19 and severe acute respiratory syndrome (SARS). Digestive viral diseases include norovirus infection, rotavirus infection, adenovirus infection and astrovirus infection. Exanthematous viral diseases include measles, rubella, chickenpox, shingles, exanthema subitum, smallpox, erythema infectiosum and chikungunya virus diseases. Liver viral diseases include hepatitis A, hepatitis B, hepatitis C, hepatitis D and hepatitis E. Skin viral diseases include warts such as genital warts, herpes labialis, genital herpes and molluscum contagiosum. Hemorrhagic viral diseases include Ebola, Lassa fever, dengue fever, yellow fever, Marburg hemorrhagic fever and Crimean-Congo hemorrhagic fever. Neuroviral diseases that may be targeted using the present invention include polio, viral meningitis, viral encephalitis and rabies.

[0155] The microorganism may be a parasitic microorganism. The infection may be caused by a pathogenic parasitic microorganism.

[0156] Examples of parasitic microorganisms that can be targeted using the present invention include protozoans.

[0157] In particular, the present invention may target protozoan groups of the subphylum Sarcophaga (e.g., Amoebae, e.g., Entamoeba genus, such as Entamoeba histolytica or Entamoeba disper), the subphylum Flagellate (e.g., Flagellates, e.g., Giardia and Leishmania), the phylum Ciliophora (e.g., Ciliates, e.g., Balantidium genus), the class Sporozoa (e.g., Plasmodium and Cryptosporidium genus) and any combination thereof.

[0158] Parasitic infections which may be treated using the present invention include malaria, amebic dysentery and leishmaniasis (eg cutaneous, mucocutaneous or visceral leishmaniasis).

[0159] In particular, the respiratory disease or disorder may be tuberculosis.

[0160] The subject may be an animal or a human subject. The term "animal" herein may generally include humans; however, when the term "animal" is used in the phrase "animal or human subject", it will be understood from the context whether it specifically refers to a non-human animal or whether the reference to "human" simply qualifies the option that the animal may be a human, to avoid any doubt.

[0161] The subject may be a human subject. The human subject may be a child or an adult subject.

[0162] The subject can be a vertebrate subject. The vertebrate can be an Agnatha (jawless fish), Chondrichthyes (cartilaginous fish), Osteichthyes (bony fish), Amphibia (amphibians), Reptilia (reptiles), Aves (birds), or Mammalia (mammals). The subject can be a Mammalian or Aves animal subject.

[0163] The subject may be a domesticated animal. Examples of domesticated animals include: - Commensals that have adapted to the human ecological niche (e.g. dogs, cats, guinea pigs) -feed or livestock intended for or raised for consumption (e.g. cattle, sheep, pigs, goats); and - Animals used primarily for draft purposes (e.g. horses, camels, donkeys) It could be one of the following.

[0164] Examples of farmed animals include, but are not limited to, alpacas, addax, bison, camels, canaries, capybara, cats, cattle (including Bali cattle), chickens, collared peccaries, deer (including fallow deer, sika deer, white-tailed deer and white-tailed deer), dogs, camels, pigeons, ducks, elands, elks, emus, ferrets, gayal, goats, geese, guinea fowl, guinea pigs, tragedies, horses, llamas, minks, moose, mice, mules, musk oxen, ostriches, parrots, pigs, feral pigeons, quails, rabbits, rats (including African reed mice), reindeer, siberian oryx, sheep, turkeys, water buffaloes, yaks and zebu cattle.

[0165] Incorporation or Encapsulation of Solid Powder Compositions in Substrates Provided herein is a material comprising a substrate and a solid powder composition disclosed herein, wherein particles of the solid powder composition are incorporated or encapsulated in the substrate. In this manner, the solid powder composition can be retained within the material by the substrate until exposed to a moist or aqueous environment.

[0166] The substrate may be of synthetic or natural polymeric type. The substrate may be, for example, polycaprolactone, polyurethane or polyacrylonitrile. The substrate may be, for example, cellulose.

[0167] The material may be a fibrous material, comprising particles of a solid powder composition incorporated or encapsulated in the fibers and fibrous material of a substrate. The particles of the solid powder composition may be exposed or partially exposed on the substrate fiber surface, or may be fully encapsulated in the fiber network and cross-section.

[0168] In some examples, the substrate is porous, and at least a portion of the particles of the solid powder composition are in the pores of the substrate. In other words, the substrate is porous and can be impregnated with the particles of the solid powder composition. In some examples, the substrate is porous by including pores in the substrate surface. In other examples, the substrate can be a porous mesh of substrate elements, such as polymeric fibers, and the particles are in the interstices between the substrate elements. As a particular example, the particles of the solid powder composition can be impregnated in the interstices of the polymeric fiber mesh.

[0169] The particles of the solid composition can have a suitable particle size for dispersing in gelling fiber.The particles of the solid composition can have a particle size of more than about 10 μm.For example, the particles of the solid composition can have a particle size of more than about 50 μm, more than about 100 μm, more than about 250 μm, more than about 500 μm, more than about 750 μm, more than about 1000 μm.

[0170] To increase the particle size, the particles may be granulated. "Granulation" refers to the process of combining particle types to form larger particles known as granules. Granulation may be performed, for example, by compressing the particles to provide tablets that can then be broken into granules. The particles may be compressed at about 1 to about 10 (metric tonnes), for example, at about 3 to about 7 MT. The particles may be compressed at about 3.8 MT. The particles may be compressed at about 6.5 MT. The tablets may be broken into granules using a sieve, for example, a 1 mm sieve.

[0171] Binders may be added to the particles to facilitate compression. Suitable binders may include sugars, natural binders, or synthetic or semi-synthetic polymeric binders. Sugar species may include, for example, sucrose or liquid glucose. Natural binders may include, for example, acacia, tragacanth, gelatin, starch paste, pregelatinized starch, alginic acid, or cellulose. Synthetic or semi-synthetic polymeric binders may include, for example, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polyvinyl alcohol, polymethacrylic acid. Binders may be copolymers of 1-vinyl-2-pyrrolidone and vinyl acetate (copovidone). Binders may be microcrystalline cellulose.

[0172] The binder may be incorporated into the composition at a % w / w of about 5% w / w to about 30% w / w. For example, the binder may be incorporated into the composition at a % w / w of about 10% w / w to about 25% w / w.

[0173] Alternatively, the composition may be substantially free of binders.

[0174] Particle size may be increased by such means to ensure that the particles are trapped (embedded or encapsulated) between the fibers.

[0175] Provided herein is a method of incorporating or encapsulating a solid powder composition of the first or second aspect in a substrate comprising the steps of: (i) mixing a solid powder composition disclosed herein with a non-polar liquid containing a substrate or substrate precursor to form a liquid-particle mixture; and (ii) solidifying the liquid-particle mixture to form a material in which the solid powder composition disclosed herein is incorporated or encapsulated.

[0176] The liquid-particle mixture may be solidified by spinning the mixture into a fiber. Techniques known to those skilled in the art for spinning fibers may be used. For example, the liquid-particle mixture may be solidified by dry spinning, wet spinning, gel spinning, or electrospinning. The liquid-particle mixture may be solidified by electrospinning. "Electrospinning" refers to a fiber production method that uses electrical forces to stretch a polymer solution or melt to a fiber diameter. The liquid-particle mixture may be solidified by gel spinning. "Gel spinning" refers to a fiber production method that utilizes temperature-induced physical gelation for solidification.

[0177] Alternatively, the solid powder particles can be incorporated into the substrate after the substrate is formed. For example, the solid powder particles can be impregnated into a porous substrate, such as a fibrous mesh substrate. In these examples, the substrate is already formed and the solid powder composition is added thereto. Specific examples of impregnating a porous substrate with a solid powder composition include those described in EP2331309 (and other techniques available from Fibroline France).

[0178] In some instances, the material is a component of topical dressing, such as wound dressing.In another embodiment, the material can be or form part of biologically implantable material or device.For example, biologically implantable material or device can be vascular and other stents, catheters, pacemakers, defibrillators, cardiac assist devices, artificial valves, electrodes, orthopedic screws and pins and other thin medical and / or implantable articles.

[0179] Coating material or device Disclosed herein is a material or device that includes a substrate and a spray-dried coating on an exterior surface of the substrate, the spray-dried coating being formed by spray drying a mixture that includes a nitrite salt solution and a proton source solution.

[0180] Also disclosed herein is a material or device that includes a substrate and a coating on an exterior surface of the substrate, the coating being a homogenous solid that includes a nitrite salt and a proton source.

[0181] As such, disclosed herein is a method of providing a material or device comprising spray drying a mixture comprising a nitrite solution and a proton source solution onto an exterior surface of a substrate to provide the material or device.

[0182] The substance or device may be a topical dressing, for example a wound dressing or bandage.

[0183] The substance or device may be an inhaler (handheld and nebulizer).

[0184] The material or device may be a biologically implantable material or device, for example, the material or device may be a vascular and other stent, catheter, pacemaker, defibrillator, cardiac assist device, prosthetic valve, electrode, orthopedic screw and pin and other thin medical and / or implantable article.

[0185] Disclosed herein are methods of implanting the disclosed materials or devices into the human or animal body.

[0186] The preferred or specific features described above may be applied to each and every aspect of the invention insofar as such features and aspects are compatible. EXAMPLES

[0187] Preparation of solid powder compositions Materials and analytical methods The following materials were obtained from commercial sources: sodium nitrite from Honeywell, citric acid from Sigma Aldrich, trisodium citrate from Merck, sodium hydroxide from Fisher, PLGA RG 502 H from Sigma Aldrich, mesoporous silica (Syloid 244FP) from Grace, dipalmitoylphosphatidylcholine (DPPC) from Avanti, Kollidon VA64 Fine from BASF, microcrystalline cellulose from JRS Pharma and dichloromethane (DCM) from Sigma Aldrich. Deionized (DI) water (18.2 MΩ) was prepared using an ELGA water purification system.

[0188] Unless otherwise stated, the following analytical methods were used:

[0189] Dry Powder Particle Size Distribution (PSD) by Sympatec Laser particle size analysis of the spray-dried powders was performed using a Sympatec HELOS particle size analyzer equipped with an R3 lens (0.5-175.0 μm range) / R5 lens (0.5-875.0 μm range) and an ASPIROS dispersion unit. Dispersion was achieved using compressed air at 3.00 bar pressure and low air pressure at 60 mbar. ASPIROS glass tubes were filled with powder in a low humidity environment (<25% RH) and sealed with parafilm until measurements were taken. Measurements were performed in triplicate unless stated otherwise and average data are reported.

[0190] Example 1: Spray drying of a mixture containing a nitrite solution and a proton source solution to form a solid powder composition A feed solution of 1.5 M sodium nitrite (Feed Solution 1) was prepared by dissolving the required amount of sodium nitrite in deionized water. A feed solution of 1 M citric acid adjusted to pH 4 (Feed Solution 2) was prepared by dissolving the required amount of citric acid in deionized water and adjusting the pH to 4 with 10 M aqueous sodium hydroxide. The pH of the solutions was measured using a Mettler Toledo Seven Compact pH meter.

[0191] Feed solutions 1 and 2 were spray dried using a Buchi B290 spray dryer equipped with a Buchi two-fluid nozzle. The two feed solutions were pumped simultaneously using a Y-piece fitting and feed lines (platinum cure silicone L / S 14 tubing) connected to a single Masterflex peristaltic pump, which combined the feed solutions just before atomization. A standard Buchi cyclone and collection pot were installed for product collection.

[0192] The feed solution was spray dried in two batches under the following conditions: [Table 1]

[0193] Both batches were then vacuum dried for 24 hours using an Edwards Super Modulyo freeze dryer set at 25°C.

[0194] Particle size distribution measurements were then performed on both batches using a Sympatec HELOS particle size analyzer equipped with an R3 lens (0.5-175.0 μm range) and an ASPIROS dispersion unit. Dispersion was achieved using compressed air at 3.00 bar pressure and low air pressure at 60 bar. Measurements were performed in triplicate.

[0195] The resulting particle size distribution measurements were as follows: [Table 2] VMD = Volume Mean Diameter

[0196] Reference Example 2: Micronization of Nitrite and Proton Source Separately and Subsequent Mixing to Produce a Solid Composition Sodium nitrite was micronized using an Atritor M3 fluid energy mill with a venturi pressure of 8 bar and a grinding pressure of 2 bar. Sodium nitrite was fed directly into the hopper at a target feed rate of approximately 2 g / min. The produced powder (Component 4A) was collected in a collection jar under low humidity (20% RH).

[0197] Citric acid and trisodium citrate were combined in weight ratios of 16.51% and 83.49%, respectively. The mixture was mixed for 10 minutes at 47 rpm using a Turbula T2F mixer.

[0198] The mixture was micronized using an Atritor M3 fluid energy mill with a venturi pressure of 8 bar and a grinding pressure of 2 bar. The mixture was fed directly into a hopper at a target feed rate of approximately 2 g / min. The produced powder (component 4B) was collected in a collection jar under low humidity (20% RH).

[0199] Micronized nitrite solids (component 2A) and micronized citric acid solids (component 2B) were then mixed in a Turbula T2F mixer at 46 rpm for 20 minutes in a ratio of 9:1 w / w citric acid solids:nitrite solids to obtain the powder composition of Reference Example 2.

[0200] NOx Emissions Examples 1A and 2 were placed in an APTAR Unidose nasal spray (https: / / www.aptar.com / products / pharmaceutical / uds / ) supported on a rig 30 cm above a Petri dish (9.8 cm diameter) containing Hanks' balanced salt solution and agarose containing a pH indicator (phenol red). Figure 1 shows the deposition pattern of the powder due to pH modification at the site of particle fall.

[0201] Immediately after application, the plates were transferred to a sealed chamber and nitrogen oxides (NOx) were measured over a 15-minute period by Single Ion Flow Tube Mass Spectrometry (SIFT-MS). All powders produced nitric oxide, regardless of production method. However, there were differences in the total amount of NOx produced over the 15-minute period between the four powders.

[0202] It should be noted that the agarose is buffered to a neutral to slightly alkaline pH, which inhibits the reaction, but the particles can overcome this buffering effect for a short period of time, antagonizing the buffering in localized areas. The table below and Figure 2 show the cumulative NO production for Examples 1A and 2. The cumulative NO / nmol / mg nitrite normalizes the experimental results to the % nitrite in the powder. [Table 3]

[0203] Coated solid powder composition Example 3: Particles coated with hydrophobic substances DPPC or mesoporous silica Example 1B was mixed with mesoporous silica in a 1:1 w / w ratio using a Turbula T2F mixer at 46 rpm for 20 minutes to obtain the powder composition of Example 3A.

[0204] Example 1B was mixed with DPPC in a 1:1 w / w ratio using a Turbula T2F mixer at 46 rpm for 20 minutes to obtain the powder composition of Example 3B.

[0205] Example 4: PLGA coated particles A PLGA RG 502 H solution was prepared by dissolving 1.5 g of PLGA in approximately 30 mL of DCM to form a clear, colorless solution. 1.5 g of Example 1B was added to this solution with stirring to form a 1:1 w / w feed suspension as a homogenous white suspension in appearance.

[0206] The feed suspension was spray dried using a Buchi B290 spray dryer according to the method detailed above. The spray drying parameters are summarized below. [Table 4]

[0207] Sample vials were maintained horizontally in individual weigh boats in a low humidity environment (28% RH). The lids were removed and the openings were covered with perforated foil (punctured using a needle). Samples were transferred to an Edwards Super Modulyo freeze dryer set at 25°C and vacuum dried for 24 hours (maximum vacuum pressure observed was approximately 0.1 mbar). After vacuum drying, samples were transferred to a low humidity (approximately 24% RH) environment and overlaid with nitrogen. The vials were then sealed in paraffin, sealed in foil pouches with desiccant, and stored at 2-8°C.

[0208] Particle size distribution measurements were then performed using a Sympatec HELOS particle size analyzer equipped with an R3 lens (0.5-175.0 μm range) and an ASPIROS dispersion unit. Dispersion was achieved using compressed air at 3.00 bar pressure and low air pressure at 60 bar. Measurements were performed in triplicate.

[0209] The resulting particle size distribution measurements were as follows: [Table 5] VMD = Volume Mean Diameter

[0210] Example 5: NOx Emissions of Coated Particles A certain amount of powder sample (30 mg) was placed on a 60 mm Petri dish. A cellulose filter paper (50 mm diameter) was placed on top of the sample and light pressure was applied. Sodium phosphate solution (10 mM, 250 μl) was added onto the cellulose filter paper. The sample was immediately placed in a 650 ml chamber, sealed, and then humid air was passed through the chamber at 650 ml / min for 30 min. The airflow from the outfeed was analyzed by Single Ion Flow Tube Mass Spectrometry (SIFT-MS). [Table 6]

[0211] Biological evaluation of solid powder compositions Example 6: Evaluation of the efficacy of four formulations against Pseudomonas aeruginosa Petri dishes containing Nutrient Agar (NA, available from AcuMedia) were prepared and allowed to solidify. Pseudomonas aeruginosa (ATCC 9027) inoculum was prepared in phosphate-buffered saline (PBS, Sigma-Aldrich) to a final concentration of 1 × 10 5 CFU mL -1 Serial dilutions were made up to 100 mL. 100 mL of the inoculum was pipetted onto an NA plate, spread and allowed to dry at room temperature for 15 minutes. The lid was removed from the inoculated agar plate and the open plate was placed into Aptar Unidose nasal spray.

[0212] An Aptar delivery device containing Example 1A or Reference Example 2 powder was connected to an Aptar nasal spray device and the powder was sprayed (approximately 50 mg amount) onto an agar plate. The table below shows the examples used in each formulation. [Table 7]

[0213] After 5 seconds, the lid of the agar plate was replaced and the agar plate was incubated for 16 hours at 37°C ± 2°C. After incubation, the plates were photographed. For every plate, three biopsy punches were taken from a 2x2cm area in the center of the agar plate. Bacteria were removed from each regime using a sterile swab presented with PBS, and every cell was suspended in 10mL PBS, then sonicated for 5 minutes, serially diluted, and plated on NA medium.

[0214] A negative control plate that was not exposed to the spray powder and a positive control plate containing 1 mL bleach were also run simultaneously. All tests were performed in triplicate.

[0215] For each test article, three replicates were randomly selected and DNA was extracted from 400 μL per biopsy using the DN easy Blood & tissue Kit (Qiagen) according to the manufacturer's instructions. Samples were eluted in AE buffer in a final volume of 100 μL.

[0216] For each extract, qPCR was performed in triplicate using the QuantiNova Pathogen and IC kit (Qiagen) according to the manufacturer's instructions. Individual reaction tubes contained final concentrations of 16 μM for each primer and 5 μM labeled probe.

[0217] Cycling conditions were as follows: 50°C for 10 min, 95°C for 2 min, 35 cycles of 95°C for 5 s, 55°C for 30 s, and 72°C for 1 min. Each assay run was validated with positive (Pseudomonas aeruginosa) and negative (RNase-free water) controls. Data were analyzed using Q-Rex software (Qiagen) to obtain Cq values ​​from a pre-determined threshold. For each sample, the average Cq value was calculated to be 1 × 10 2 ~1×10 8 CFU mL -1 Compare with a standard curve in the established range of Log 10 CFU mL -1 The final sample concentration was calculated as:

[0218] Table 1: 1×10 after treatment with formulations 1 and 2 and bleach compared to untreated negative control 5 CFU mL -1 Mean recovery and reduction of Pseudomonas aeruginosa from three biopsy punches taken from the center of nutrient agar plated with 0.01% ethanol (N=5). [Table 8] SD=standard deviation, CFU=colony forming units, N / A=not applicable, *=p<0.05, **=p<0.01, ***=p<0.001.

[0219] Biopsies taken from negative control plates had a mean of 7.44 ± 0.17 Log 10 CFU mL -1 Pseudomonas aeruginosa recovery was observed in the biopsies taken from preparation 2, with a mean of 1.36 ± 2.13 Log 10 CFU mL -1No viable Pseudomonas aeruginosa was recovered from biopsies taken from formulation 1 or the positive control plates, where Pseudomonas aeruginosa recovery was observed.

[0220] Table 2: 1×10 after treatment with formulations 1 and 2 and bleach compared to untreated negative control. 5 CFU mL -1 Molecular quantification of Pseudomonas aeruginosa in biopsy punches taken from nutrient agar plated with erythrocytes. [Table 9] SD = standard deviation, CFU = colony forming units. # = Quantification was below the limit of detection. ~ = Positive control sample quantification was performed on N=1, therefore standard deviations were not calculated. N / A=not applicable, **=p<0.01, ***=p<0.001.

[0221] After treatment with formulation 1, 1 × 10 5 CFU mL -1 A significant reduction in the recovery of viable Pseudomonas aeruginosa was observed in biopsies taken from nutrient agar plates seeded with the inoculum. The powder was compared to an untreated negative control, as no viable Pseudomonas aeruginosa was recovered. Molecular quantification reflects recovery from colony counts.

[0222] Example 7: Effect of powder composition on sprouting of human umbilical vein endothelial cells (HUVEC) in a spheroid-based cellular angiogenesis assay . Ten-fold concentrated stock solutions / suspensions of Examples 1B and 4A were prepared in defined medium (without supplements and FCS) by vortexing and pipetting. Semi-logarithmic dilution series were then prepared in the same medium. [Table 10]

[0223] endothelial cells Cells: HUVEC, primary human umbilical vein endothelial cells (PromoCell, Heidelberg, Germany), passage 3–4. Morphology: Attached, cobblestone-like growth as a monolayer Culture medium: Endothelial cell growth and basal medium (ECGM / ECBM, PromoCell) Subculture: Split 1:3; every 3-5 days, approximately 1 × 10 4 cells / cm 2 Sow seeds and put them out Incubation: 37℃, 5% CO2 Doubling time: 24~48 hours Save: approx. 1 x 10 6 Cells / ampoule frozen with 70% medium, 20% FCS, 10% DMSO Origin: Human umbilical vein, pooled donor

[0224] Test Method The experiments were performed with modifications of the original published protocol (Korff and Augustin: J Cell Sci 112: 3249-58, 1999). Briefly, spheres were prepared as described (Korff and Augustin: J Cell Biol 143: 1341-52, 1998) by pipetting 400 HUVECs in hanging drops on a plastic dish and allowing the spheroids to aggregate overnight. 50 HUVEC spheroids were then seeded in 0.9 ml of collagen gel and pipetted into individual wells of a 24-well plate and allowed to polymerize. Preincubated test samples were added after 30 min by pipetting 100 μl of a 10x working solution on top of the polymerized gel (final assay concentrations see Table 1). Plates were incubated at 37° C. for 24 h and fixed by adding 4% PFA (Roth, Karlsruhe, Germany).

[0225] Quantification The sprouting intensity of HUVEC spheroids treated with test samples was quantified by an image analysis system that determined the cumulative sprout length (CSL) per spheroid. Photographs of single spheroids were taken using an inverted microscope and digital imaging software NIS-Elements BR 3.0 (Nikon). The old photographs were then uploaded to the Wimasis website for image analysis. The cumulative sprout length of each spheroid was determined using the image analysis tool WimSprout. The average cumulative sprout length of 10 randomly selected spheroids was analyzed from each data point. The mean and SD values ​​of each triplicate were converted to % of basal control.

[0226] result Figure 3 shows CSL against basal control of Examples 1B and 4A. The effect of Example 1B (spray-dried particles without coating) is small compared to the basal control. In contrast, PLGA-coated particles of Example 4A show a significant dose-dependent effect compared to the basal control. This indicates that coated particles provide a local environment that allows for nitrite acidification, despite being in a substantially neutral environment.

[0227] Example 8: SEM / EDX study of spray-dried powders SEM / EDX was used to assess the microstructure and contribution of various components in the final formulation of the powder produced by the method of Example 1.

[0228] experiment The spray dried powder was stored in a freezer and subsequently sampled. Initial preparation for SEM / EDX examination involved sprinkling the powder onto a carbon adhesive disk on the SEM stage. A similar approach was then used, but with gentle compression of the powder, for clearer elemental mapping applications.

[0229] In both cases, prepared sections were examined in uncoated and low vacuum mode using an FEI Quanta FEG 250 environmental SEM with an associated Quantax 200 microanalysis system for elemental analysis.

[0230] result SEM images of the spray dried powder showed that discrete spheres were observed, primarily ranging from submicron to about 6 or 7 microns in diameter, and these images are shown in FIG.

[0231] The EDX analysis also showed carbon, oxygen, sodium and nitrogen. The presence of nitrogen is indicative of nitrite content and the presence of carbon is indicative of the presence of citric acid. The EDX analysis is shown in Figure 5.

[0232] The images in Figure 6 show EDX maps of nitrogen (green) versus backscattered electron image (BSE) and nitrogen (blue) versus carbon for the spray-dried formulation at 2000x microscope magnification. The accompanying BSE image is also included to identify particle characteristics. At this increased magnification, the uniformity of the spray-dried formulation is evident, with individual particles appearing to show contributions from both carbon and nitrogen.

Claims

1. A solid powder composition comprising one or more particles comprising a nitrite salt and a proton source.

2. A solid powder composition comprising particles formed by spray drying a mixture comprising one or more nitrite salt solutions and a proton source solution.

3. A solid powder composition comprising particles coated with a hydrophobic material, wherein the coated particles are particles comprising a nitrite salt and a proton source, and are coated with a hydrophobic material.

4. A pharmaceutical composition comprising the solid powder composition of any one of claims 1 to 3 and optionally one or more additives and / or adjuvants.

5. A method of producing a solid powder composition comprising spray drying a mixture comprising a nitrite solution and a proton source solution to form a solid powder.

6. (i) Coating particles containing nitrite and a proton source with a hydrophobic material.

1. A method for producing a solid powder composition comprising particles coated with a hydrophobic material, comprising the steps of:

7. A solid powder composition according to any one of claims 1 to 3 for treating or preventing a respiratory disease or disorder.

8. A pharmaceutical composition of claim 4 for treating or preventing a respiratory disease or disorder.

9. 4. A substance comprising a substrate and the solid powder composition of any of claims 1 to 3, wherein particles of the solid powder composition are incorporated or encapsulated in the substrate.

10. A method of incorporating or encapsulating the solid powder composition of any of claims 1 to 3 in a substrate, comprising the steps of: (i) mixing the solid powder composition of any of claims 1 to 3 with a non-aqueous liquid containing a substrate or a substrate precursor to form a liquid-particle mixture; and (ii) solidifying the liquid-particle mixture to form a material that incorporates or encapsulates the solid powder composition of any of claims 1 to 3.

11. A material or device comprising a substrate and a spray-dried coating on an exterior surface of the substrate, the spray-dried coating being formed by spray drying a mixture comprising a nitrite solution and a proton source solution.

12. A material or device comprising a substrate and a coating on an exterior surface of the substrate, the coating being a homogeneous solid comprising nitrite and a proton source.

13. A method of providing a material or device comprising spray drying a mixture comprising a nitrite solution and a proton source solution onto an exterior surface of a substrate to provide the material or device.

14. A substance or device according to claim 12 or claim 13, implanted in the human or animal body.

Images